

INDIANA HEALTH COVERAGE PROGRAMS (IHCP) PHARMACY BENEFIT TESTOSTERONES PRIOR AUTHORIZATION REQUEST FORM



CareSource Pharmacy Prior Authorization Form P.O. Box 8738 Dayton, OH 45401-8738 Fax: (866) 930-0019

Today's Date		Non-U	rgent	Urgent
Note: This form must be completed by the prescribing provider. ***All sections must be completed or the request will be returned.***				
Patient's	iust be completed	- i	iii be returnea.***	
CareSource #		Date of Birth		/
Patient's Name		Prescriber's Nan	ne	
Prescriber's IN License #		Specialty		
Prescriber's NPI #		Office Contact	Office Contact	
Prescriber's Fax:	-	Prescriber's Pho	ne	
Prescriber's Address		Date(s) of Service Start Date:	e:	
Diagnosis		Diagnosis Code		
Requested Medication	Strength	Quantity	Direction	ns for Use
DEPO-TESTOSTERONE, TESTOST	TERONE CYPION	ATE		
Initial Authorization: 1. Please select one of the following: Member has a diagnosis of d Member has a total testostere	elayed puberty	/dL within the past	3 months (Docume	entation is required)
2. For ALL indications:				
Provider attests that member has a Breast cancer in a member has a Pregnancy Prostate cancer		•	ns to therapy: □ Y	′es □ No
If no , please specify contrain	dication and medic	cal rationale for us	e :	
Prescriber Signature:			Date:	
1				

Reauthorization: 1. Total testosterone level is ≤1000 ng/dL within the past 6 months (Documentation is required) ☐ Yes ☐ No		
2. Provider attests that member remains a candidate for treatment, indicating that they have not developed any of the contraindication(s) listed under initial authorization above \square Yes \square No		
If no , please specify contraindication and medical rationale for use:		
Prescriber Signature: Date:		
ESTOSTERONE ENANTHATE		
nitial Authorization: . Please select one of the following:		
☐ Member has a diagnosis of delayed puberty		
 Has the member had a previous trial and failure of ALL preferred injectable testosterone agents 		
(reference PA criteria)? ☐ Yes ☐ No		
If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:		
 Member has a total testosterone level ≤ 350 ng/dL within the past 3 months (Documentation is required) Has the member had a previous trial and failure of ALL preferred injectable testosterone agents (reference PA criteria)? ☐ Yes ☐ No If no, please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents: 		
☐ Member needs medication for palliative treatment of metastatic breast cancer		
 For ALL indications: Provider attests that member has none of the following contraindications to therapy: Yes No Breast cancer in a member assigned male at birth Pregnancy Prostate cancer 		
If no , please specify contraindication and medical rationale for use:		
Prescriber Signature: Date:		
Reauthorization: Total testosterone level is ≤1000 ng/dL within the past 6 months (Documentation is required) □ Yes □ No		
. Has the member had a previous trial and failure of at least ONE preferred injectable testosterone agent (not required for palliative treatment of breast cancer) [reference PA criteria]? \square Yes \square No		

If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:				
3. Provider attests that member remains a candidate for treatment, indicating that they have not developed any of the contraindication(s) listed under initial authorization above \square Yes \square No				
If no , please specify contraindication and medical rationale for use:				
				
Prescriber Signature: Date:				
AVEED, TESTOPEL PELLET, XYSOTED				
Initial Authorization: 1. Please select one of the following:				
☐ Member has a diagnosis of delayed puberty				
 Has the member had a previous trial and failure of ALL preferred injectable testosterone agents (reference PA criteria)? ☐ Yes ☐ No 				
If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:				
 Member has a total testosterone level ≤ 350 ng/dL within the past 3 months (Documentation is required) Has the member had a previous trial and failure of ALL preferred injectable testosterone agents (reference PA criteria)? ☐ Yes ☐ No 				
If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:				
2. For ALL indications: Provider attests that member has none of the following contraindications to therapy: □ Yes □ No ■ Breast cancer in a member assigned male at birth ■ Hypogonadal conditions not associated with structural or genetic etiologies (Xyosted ONLY) ■ Pregnancy ■ Prostate cancer				
If no , please specify contraindication and medical rationale for use:				
Prescriber Signature: Date:				
Reauthorization:				
1. Total testosterone level is ≤1000 ng/dL within the past 6 months (Documentation is required) ☐ Yes ☐ No				
2. Has the member had a previous trial and failure of at least ONE preferred injectable testosterone agent (reference PA criteria)? ☐ Yes ☐ No				

	If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:
	vider attests that member remains a candidate for treatment, indicating that they have not developed any of contraindication(s) listed under initial authorization above \square Yes \square No
	If no , please specify contraindication and medical rationale for use:
Pres	criber Signature: Date:
	OSTERONE 1% (25 MG)/ 2.5 GM GEL PACKETS, TESTOSTERONE 1% (12.5 MG)/ACT GEL PUMP, OSTERONE 1.62% (20.25 MG)/ACT METERED PUMP GEL, TESTIM 1% (50 MG)/5 GM GEL PACKETS
1. Plea	Authorization: ase select one of the following: Member is 16 years of age or older, has a total testosterone level ≤ 350 ng/dL within the past 3 months (Documentation is required), and is requesting to use topical testosterone within the established quantity limits
	Requested dose:
	Member is 16 years of age or older, has a total testosterone level ≤ 400 ng/dL while on topical testosterone therapy (Documentation is required) and is requesting to exceed established quantity limits
	Requested dose:
	Member has utilized ≥ 14 days of topical testosterone therapies □ Yes □ No
	Name of medication:
	Dose:
	Start and End date:
	If no , please provide medical justification as to why member is requesting a dose beyond established quantity limits:
	ALL indications: vider attests that member has none of the following contraindications to therapy: ☐ Yes ☐ No • Breast cancer in a member assigned male at birth • Pregnancy • Prostate cancer If no, please specify contraindication and medical rationale for use:
Presc	riber Signature: Date:

Reauthorization:		
1. Total testosterone level is ≤1000 ng/dL within the past 6 months (Documentation is required) ☐ Yes ☐ No		
2. Provider attests that member remains a candidate for treatment, indicating that they have not developed any of the contraindication(s) listed under initial authorization above \square Yes \square No		
If no , please specify contraindication and medical rationale for use:		
Prescriber Signature: Date:		
NATESTO, TESTOSTERONE 1% (12.5 MG)/ACT GEL PUMP, TESTOSTERONE 1.62% (40.5 MG)/2.5 GM GEL PACKETS, TESTOSTERONE 1.62% (20.25 MG)/1.25 GM GEL PACKETS, TESTOSTERONE 2% (10 MG)/ACT METERED PUMP, TESTOSTERONE 30 MG/ACT SOLUTION, VOGELXO 1% (50 MG)/5 GM GEL PACKETS, VOGELXO 1% (12.5 MG)/ACT GEL PUMP		
Initial Authorization: 1. Please select one of the following:		
 ☐ Member is 16 years of age or older, has a total testosterone level ≤ 350 ng/dL within the past 3 months (Documentation is required), and is requesting to use topical testosterone within the established quantity limits 		
Requested dose:		
Requested dose:		
Member has utilized ≥ 14 days of topical testosterone therapies: □ Yes □ No		
Name of medication:		
Dose: Start and End date:		
Otalt and Lind date		
If no , please provide medical justification as to why member is requesting a dose beyond established quantity limits:		
2. Previous trial and failure of ALL preferred topical testosterone agents (reference PA criteria) \square Yes \square No		
If no , please provide medical justification for use of requested agent over ALL preferred topical testosterone agents:		
 3. For ALL indications: Provider attests that member has none of the following contraindications to therapy: ☐ Yes ☐ No Breast cancer in a member assigned male at birth Pregnancy 		

Prostate cancer	
If no , please specify contraindication and medical rationale for use:	
Prescriber Signature: Date:	_
eauthorization:	
Total testosterone level is ≤1000 ng/dL within the past 6 months (Documentation is required) ☐ Yes ☐ No	
Previous trial and failure of at least ONE preferred topical testosterone agent $\ \square$ Yes $\ \square$ No	
If no , please provide medical justification for use of requested agent over ALL preferred topical testosterone agents:	
Provider attests that member remains a candidate for treatment, indicating that they have not developed a the contraindication(s) listed under initial authorization above \square Yes \square No If no , please specify contraindication and medical rationale for use:	ny of
Prescriber Signature: Date:	_
Prescriber Signature: Date:	-
Prescriber Signature: Date: nitial Authorization (approval up to 6 months):	_
	_
nitial Authorization (approval up to 6 months):	
nitial Authorization (approval up to 6 months): . Member diagnosis(es): lote: Approvable diagnoses include angioedema prophylaxis for heredity angioedema, autoimmune hemolytic anemia, discupus erythematosus, endometriosis, fibrocystic breast disease, myelosclerosis with myeloid metaplasia	
nitial Authorization (approval up to 6 months): . Member diagnosis(es): lote: Approvable diagnoses include angioedema prophylaxis for heredity angioedema, autoimmune hemolytic anemia, disc	
nitial Authorization (approval up to 6 months): . Member diagnosis(es): lote: Approvable diagnoses include angioedema prophylaxis for heredity angioedema, autoimmune hemolytic anemia, discupus erythematosus, endometriosis, fibrocystic breast disease, myelosclerosis with myeloid metaplasia	
nitial Authorization (approval up to 6 months): . Member diagnosis(es): dote: Approvable diagnoses include angioedema prophylaxis for heredity angioedema, autoimmune hemolytic anemia, discupus erythematosus, endometriosis, fibrocystic breast disease, myelosclerosis with myeloid metaplasia Provider attests that member has none of the following contraindications to therapy: Active or history of thrombosis or thromboembolic disease Androgen-dependent tumor	
nitial Authorization (approval up to 6 months): . Member diagnosis(es): lote: Approvable diagnoses include angioedema prophylaxis for heredity angioedema, autoimmune hemolytic anemia, discupus erythematosus, endometriosis, fibrocystic breast disease, myelosclerosis with myeloid metaplasia 2. For ALL indications: Provider attests that member has none of the following contraindications to therapy: • Active or history of thrombosis or thromboembolic disease • Androgen-dependent tumor • Cardiac disease	
nitial Authorization (approval up to 6 months): . Member diagnosis(es):	
nitial Authorization (approval up to 6 months): . Member diagnosis(es): . Member diagnoses include angioedema prophylaxis for heredity angioedema, autoimmune hemolytic anemia, discupus erythematosus, endometriosis, fibrocystic breast disease, myelosclerosis with myeloid metaplasia 2. For ALL indications: Provider attests that member has none of the following contraindications to therapy: • Active or history of thrombosis or thromboembolic disease • Androgen-dependent tumor • Cardiac disease • Porphyria • Pregnancy or breast-feeding	
nitial Authorization (approval up to 6 months): . Member diagnosis(es): . Member diagnoses include angioedema prophylaxis for heredity angioedema, autoimmune hemolytic anemia, discupus erythematosus, endometriosis, fibrocystic breast disease, myelosclerosis with myeloid metaplasia 2. For ALL indications: Provider attests that member has none of the following contraindications to therapy: • Active or history of thrombosis or thromboembolic disease • Androgen-dependent tumor • Cardiac disease • Porphyria • Pregnancy or breast-feeding	
nitial Authorization (approval up to 6 months): . Member diagnosis(es):	
nitial Authorization (approval up to 6 months): . Member diagnosis(es): lote: Approvable diagnoses include angioedema prophylaxis for heredity angioedema, autoimmune hemolytic anemia, discupus erythematosus, endometriosis, fibrocystic breast disease, myelosclerosis with myeloid metaplasia 2. For ALL indications: Provider attests that member has none of the following contraindications to therapy: Yes No Active or history of thrombosis or thromboembolic disease Androgen-dependent tumor Cardiac disease Porphyria Pregnancy or breast-feeding Severe hepatic disease Severe renal disease	
nitial Authorization (approval up to 6 months): . Member diagnosis(es):	
nitial Authorization (approval up to 6 months): . Member diagnosis(es):	

Reauthorization (approval up to 6 months):			
. Documentation from prescriber indicating continued benefit from the medication without significant adverse events $\;\square$ Yes \square No			
2. Provider attests that member remains a candidate for treatment, indicating that they have not developed any of the contraindication(s) listed under initial authorization above \square Yes \square No			
If no , please specify contraindication and medical rationale for use:			
Prescriber Signature: Date:			
ATENZO (TESTOSTERONE UNDECANOATE):			
nitial Authorization: . Member is 18 years of age or older \square Yes $\ \square$ No			
. Member has a diagnosis of hypogonadism with a total testosterone level \leq 350 ng/dL within the past 3 months (Documentation is required) \square Yes \square No			
. Previous trial and failure of at least ONE preferred injectable testosterone agent (reference PA criteria)			
☐ Yes ☐ No			
If no , please provide medical justification for use of requested agent over ALL preferred injectable			
testosterone agents:			
. For ALL indications:			
Provider attests that member has none of the following contraindications to therapy: ☐ Yes ☐ No ■ Breast cancer in a member assigned male at birth			
Hypogonadal conditions not associated with structural or genetic etiologiesPregnancy			
 Prostate cancer If no, please specify contraindication and medical rationale for use: 			
Prescriber Signature: Date:			
Reauthorization:			
. Total testosterone level is ≤ 1000 ng/dL within the past 6 months (Documentation is required) ☐ Yes ☐ No			
. Provider attests that member remains a candidate for treatment, indicating that they have not developed any of the contraindication(s) listed under initial authorization above \square Yes \square No	of		
If no , please specify contraindication and medical rationale for use:			
Prescriber Signature: Date:			

3. Previous trial and failure of at least ONE preferred injectable testosterone agent (reference PA criteria) Yes No If no, please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:
KYZATREX (TESTOSTERONE UNDECANOATE):
Initial Authorization: 1. Member is 18 years of age or older □ Yes □ No
2. Member has a diagnosis of hypogonadism and a total testosterone level ≤ 350 ng/dL within the past 3 months (Documentation is required) ☐ Yes ☐ No
3. Previous trial and failure of at least ONE preferred injectable testosterone agent (reference PA criteria) ☐ Yes ☐ No
If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:
 4. For ALL indications: Provider attests that member has none of the following contraindications to therapy: ☐ Yes ☐ No ■ Breast cancer ■ Hypogonadal conditions not associated with structural or genetic etiologies ■ Pregnancy ■ Prostate cancer If no, please specify contraindication and medical rationale for use:
Prescriber Signature: Date:
Reauthorization:
1. Total testosterone level is ≤ 1000 ng/dL within the past 6 months (Documentation is required) ☐ Yes ☐ No
2. Provider attests that member remains a candidate for treatment, indicating that they have not developed any of the contraindication(s) listed under initial authorization above \square Yes \square No
If no , please specify contraindication and medical rationale for use:
Prescriber Signature: Date:
3. Previous trial and failure of at least ONE preferred injectable testosterone agent (reference PA criteria)
☐ Yes ☐ No If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:

METHITEST (METHYLTESTOSTERONE) Initial Authorization (approval up to 6 months): 1. Please select one of the following: ☐ Member has a diagnosis of cryptorchidism ☐ Member has a diagnosis of delayed puberty Member has a diagnosis of hypogonadism (primary or hypogonadotropic) with a total testosterone ≤ 350 ng/dL within the past 3 months (Documentation is required) ☐ Member needs medication for palliative treatment of metastatic breast cancer 2. Previous trial and failure of at least ONE preferred injectable testosterone agent (reference PA criteria) ☐ Yes ☐ No If no, please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents: 3. For **ALL** indications: Provider attests that member has none of the following contraindications to therapy: ☐ Yes ☐ No Breast cancer in a member assigned male at birth Pregnancy • Prostate cancer If **no**, please specify contraindication and medical rationale for use: Prescriber Signature: _____ Date: _____ Reauthorization (approval up to 6 months): 1. Please select one of the following: ☐ Member has a diagnosis of hypogonadism and a total testosterone level ≤ 1000 ng/dL within the past 6 months (Documentation is required) ☐ Member has a diagnosis of delayed puberty, palliative treatment of metastatic breast cancer, or cryptorchidism AND prescriber has submitted documentation indicating continued benefit from the medication without significant adverse events: 2. For **ALL** indications: Provider attests that member remains a candidate for treatment, indicating that they have not developed any of the contraindication(s) listed under initial authorization above \square Yes \square No If **no**, please specify contraindication and medical rationale for use: ____ Date: ____ Prescriber Signature: _____ 3. Previous trial and failure of at least ONE preferred injectable testosterone agent (reference PA criteria) ☐ Yes ☐ No If no, please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:

OXANDRIN (OXANDROLONE):			
Initial Authorization (approval up to 6 months):			
1. Member diagnosis(es):			
Note: Approvable diagnoses include adjunct treatment of severe burns during the catabolic and rehabilitative phases, AIDS-associated wasting syndrome, alcoholic hepatitis, cachexia			
2. For ALL indications:			
Provider attests that member has none of the following contraindications to therapy: \Box Yes \Box No			
 Breast cancer Hypercalcemia Pregnancy Prostate cancer Severe renal disease 			
If no , please specify contraindication and medical rationale for use:			
Prescriber Signature: Date:			
Reauthorization (approval up to 6 months):			
 Documentation from prescriber indicating continued benefit from the medication without significant adverse events ☐ Yes ☐ No 			
2. Provider attests that member remains a candidate for treatment, indicating that they have not developed any of the contraindication(s) listed under initial authorization above ☐ Yes ☐ No			
If no , please specify contraindication and medical rationale for use:			
Prescriber Signature: Date:			
TLANDO (TESTOSTERONE UNDECANOATE)			
Initial Authorization: 1. Member is 18 years of age or older □ Yes □ No			
2. Member has a diagnosis of hypogonadism and a total testosterone level ≤ 350 ng/dL within the past 3 months (Documentation is required) ☐ Yes ☐ No			
3. Previous trial and failure of at least ONE preferred injectable testosterone agent (reference PA criteria) ☐ Yes ☐ No			
If no , please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:			
 4. For ALL indications: Provider attests that member has none of the following contraindications to therapy: ☐ Yes ☐ No ■ Breast cancer 			

 Hypogonadal conditions not associated with structural or genetical pregnancy Prostate cancer If no, please specify contraindication and medical rationale for use:	ic etiologies	
Prescriber Signature:		
Reauthorization: 1. Total testosterone level is ≤ 1000 ng/dL within the past 6 months (Docur	mentation is required) Yes No	
2. Prescriber attests that member remains a candidate for treatment, indica of the contraindication(s) listed under initial authorization above ☐ Yes ☐ If no , please specify contraindication and medical rationale for use:		
Prescriber Signature:		
3. Previous trial and failure of at least ONE preferred injectable testosterone agent (reference PA criteria) Yes No If no, please provide medical justification for use of requested agent over ALL preferred injectable testosterone agents:		
I attest that the provided information above is accurate:		
Physician Signature:	Date:	